. 2011 May;13(3):297–304. doi: 10.1016/j.jmoldx.2010.12.003

Table 2.

Training and Validation Series Details, Group Size, Demographic Description, and Multivariate Cox Proportional Hazards Analysis Output (DMFS and OS)

Series	Description	Covariate	DMFS P value^⁎	DMFS HR (95% CI)	OS P value^†	OS HR (95% CI)
Training: GSE4922, Ivshina et al,¹²; GSE6532, Loi et al¹¹ (N = 477)	ER⁺/ER^-, N0/N1, systemic therapy, tamoxifen only, or no adjuvant therapy	Age	0.42	1.01 (0.99–1.02)
		ER⁺	0.58	1.18 (0.65–2.16)
		Grade	0.059	1.40 (0.99–1.97)
		Size	0.10	1.01 (1.00–1.02)
		Node⁺	0.0001^‡	2.79 (1.67–4.66)^‡
		Endocrine therapy	0.28	0.73 (0.42–1.28)
		Chemotherapy	0.0032^‡	0.35 (0.18–0.70)^‡
		200-Gene signature	0.0001^‡	3.14 (1.80–5.49)^‡
Validation 1: GSE7390, Desmedt et al¹³ (N = 198)	ER⁺/^–, N0, <61 years, untreated, ≤5 cm	Age	0.35	1.022 (0.98–1.07)	0.46	1.02 (0.97–1.06)
		ER⁺	0.54	0.81 (0.40–1.62)	0.033^‡	0.48 (0.25–0.94)^‡
		Grade	0.73	1.11 (0.63–1.95)	0.23	0.74 (0.45–1.21)
		Size	0.092	1.35 (0.95–1.92)	0.074	1.35 (0.97–1.87)
		200-Gene signature	0.0046^‡	4.37 (1.58–12.08)^‡	0.0053^‡	3.31 (1.43–7.64)^‡
Validation 2: GSE11121, Schmidt et al¹⁴ (N = 200)	ER⁺/^–, untreated, population based, N0	Grade	0.033^‡	1.93 (1.057–3.51)^‡
		Size	0.79	1.044 (0.75–1.45)
		200-Gene signature	0.056	2.63 (0.98–7.055)
Validation 3: GSE1456, Pawitan et al¹⁵ (N = 159)	ER⁺/^–, population based, 126 received adjuvant therapy	Grade	0.19	1.47 (0.83–2.64)	0.34	1.40 (0.70–2.80)
Validation 3: GSE1456, Pawitan et al¹⁵ (N = 159)	ER⁺/^–, population based, 126 received adjuvant therapy	200-Gene signature	0.055	2.58 (0.98–6.67)	0.025^‡	4.67 (1.23–17.81)^‡
Validation 4: GSE9195 and GSE6532, Loi et al¹¹ (N = 128)	ER⁺, adjuvant tamoxifen treated, N0/N1, ≤5 cm	Age	0.22	0.97 (0.93–1.019)
		Grade	0.74	0.89 (0.46–1.72)
		Nodes	0.94	0.96 (0.38–2.38)
		Size	0.0075^‡	1.49 (1.11–1.98)^‡
		200-Gene signature	0.019^‡	6.51 (1.37–30.86)^‡
Validation 5: NKI 295, Van De Vijver et al¹⁶ (N = 295)^§	ER⁺/^–, untreated, stage I/ II, <53 years; N0/N1	ER⁺	0.18	0.74 (0.47–1.16)	0.057	0.51 (0.32–0.82)
		Node⁺	0.39	0.84 (0.56–1.25)	0.63	0.90 (0.57–1.40)
		99-Gene signature	<0.0001^‡	2.92 (1.77–4.80)^‡	<0.0001^‡	3.91 (2.06–7.42)^‡

GSE numbers are the National Center for Biotechnology Information Gene Expression Omnibus entry for each series.

GSE, GEO Series; N0, lymph node negative; N1, lymph node positive; NKI, Nederlands Kanker Instituut (Netherlands Cancer Institute).

^⁎

Value for RFS in the training series and for DMFS in the validation 1, 3, 4, and 5 series.

^†

Value for OS in the validation 1 and 5 series and DSS in the validation 3 series. OS details for other series not available.

^‡

Statistically significant variables within each CPH model.

^§

Validation series 5 was generated using a custom oligonucleotide microarray containing 99 of the 200 genes used by the classifier.

Data were obtained from Rosetta Inpharmatics, Seattle, WA (http://www.rii.com/publications/2002/nejm.html, last accessed March 3, 2011).